Atyr Pharma and the U.S. Food and Drug Administration (FDA) have aligned on the specific main outcome analysis of the ongoing Phase 3 clinical trial that’s testing the company’s investigational therapy efzofitimod in people with pulmonary sarcoidosis. Based on FDA feedback during a recent type C meeting,…
News
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to better understand the real-world lived experiences of people in the U.S. with rare diseases. Living Rare, the first large-scale study of its kind in the U.S., seeks to capture the…
The U.S. Food and Drug Administration (FDA) has approved a prefilled syringe version of purified Cortrophin Gel (repository corticotropin injection) as an add-on treatment for people with symptoms of sarcoidosis. Sold by Ani Pharmaceuticals, the original vial format of Corticotrophin Gel received FDA clearance in 2021 to treat…
Autoimmune responses against healthy proteins in the retina, which is the back of the eye, could play a role in driving a type of eye inflammation called uveitis in people with ocular sarcoidosis, per a new study. According to the researchers, self-reactive antibodies against the retina were found more…
People with sarcoidosis who live in the U.S. are most concerned about their disease worsening, developing in more organs, or not lessening, according to the results of an online survey developed by both patients and doctors that was used to query more than 1,000 individuals. Per the findings, patients…
Roivant Sciences is planning to launch a Phase 2 clinical trial this year to test its experimental oral therapy brepocitinib in adults with cutaneous sarcoidosis. The company said it expects to start the trial between April and June, and that the study’s results should become available in the…
The Foundation for Sarcoidosis Research (FSR) has granted $300,000 in funding to support three scientists embarking on research studies that could lead to advancements in the diagnosis or treatment of sarcoidosis, or in patient care. Each of the three researchers was awarded $100,000 through the FSR’s Pilot…
Cutaneous sarcoidosis patients with lesions on the head and face are significantly more likely to also have cardiac sarcoidosis, which is when the disease reaches the heart, a small study in the U.S. suggests. The findings indicate the distribution of skin lesions is linked to the risk of…
Blood levels of high-sensitivity cardiac troponin T (hs-cTnT), a marker of heart muscle damage, may serve as a prognostic biomarker for adverse events, including death and heart failure, in people with cardiac sarcoidosis, a study in Japan shows. Patients with combined elevated levels of both hs-cTnT and B-type natriuretic…
Black people with sarcoidosis have longer delays in referrals to multidisciplinary care, according to a recent study. Treatment of sarcoidosis changed in 78% of patients after a referral, with no significant differences in race, sex, or ethnicity between those who underwent a change to clinical management and those who…
Recent Posts
- Simple blood test may predict cardiac sarcoidosis outcomes
- To scoot or not to scoot: Using a mobility aid with a dynamic disability
- Mobile app for breathing meditation may reduce sarcoidosis fatigue
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF
- A holiday gift guide for your loved one with sarcoidosis
- FSR gathers global leaders to drive progress in sarcoidosis research
- New genetic clues connect sarcoidosis with lung cancer risk
- When patients and caregivers swap roles, empathy usually follows